Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.35 |
| ▸ | HTR3B | O95264 | 1/20 | 0.35 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.35 |
| ▸ | HTR3A | P46098 | 1/20 | 0.35 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.35 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.35 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.34 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.34 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 2/20 | 0.33 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27513171 | 0.93 | LMNA (0.43) | LMNASIGMAR1MEN1KMT2ANPC1 | |
| SCHEMBL2340643 | 0.84 | LMNA (0.34) | LMNAMEN1KMT2AHSD17B10ALOX5 | |
| SCHEMBL28073187 | 0.78 | — | — | |
| SCHEMBL10648796 | 0.78 | ADRB1 (0.39) | LMNAMEN1KMT2ANPC1RAB9A | |
| SCHEMBL11593810 | 0.77 | CHRNB2 (0.47) | CHRNA7CYP3A4CHRNB2CHRNA3CHRNA4 | |
| SCHEMBL10515874 | 0.74 | HTR3E (0.44) | SIGMAR1KMT2ARAB9AHTR3EHTR3B | |
| SCHEMBL21752062 | 0.72 | LMNA (0.41) | LMNASIGMAR1MEN1KMT2ANPC1 | |
| SCHEMBL1406399 | 0.72 | — | — | |
| SCHEMBL6049417 | 0.71 | LMNA (0.43) | LMNASIGMAR1MEN1KMT2ANPC1 | |
| SCHEMBL17027625 | 0.71 | MEN1 (0.41) | MEN1KMT2ACYP2C9CYP2C19L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112023662-B | Composite desulfurizer for purifying petroleum and natural gas | 宁波中一石化科技有限公司 | 2021-07-02 | — | — | CN | claimed |
| CN-112023662-A | Composite desulfurizer for purifying petroleum and natural gas | 宁波中一石化科技有限公司 | 2020-12-04 | — | — | CN | claimed |
| CN-107866147-B | Preparation method of offshore oilfield liquid composite desulfurizer | 中海油天津化工研究设计院有限公司 | 2020-10-30 | — | — | CN | claimed |
| US-20240109882-A1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | GENZYME CORP (US) | 2024-04-04 | — | — | US | disclosed |
| US-11897876-B2 | Isoxazolidines as RIPK1 inhibitors and use thereof | GENZYME CORPORATION (US) | 2024-02-13 | — | — | US | disclosed |
| US-20230203027-A1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | GENZYME CORPORATION | 2023-06-29 | — | — | US | disclosed |
| WO-2023083847-A1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | SANOFI (FR) | 2023-05-19 | — | — | WO | disclosed |
| CN-112023662-B | Composite desulfurizer for purifying petroleum and natural gas | 宁波中一石化科技有限公司 | 2021-07-02 | — | — | CN | disclosed |
| CN-112023662-A | Composite desulfurizer for purifying petroleum and natural gas | 宁波中一石化科技有限公司 | 2020-12-04 | — | — | CN | disclosed |
| CN-107866147-B | Preparation method of offshore oilfield liquid composite desulfurizer | 中海油天津化工研究设计院有限公司 | 2020-10-30 | — | — | CN | disclosed |
| CN-108602809-A | Inhibitors of isoxazolidine derived receptor interacting protein kinase 1(RIPK 1) | 戴纳立制药公司 | 2018-09-28 | — | — | CN | disclosed |
| EP-2585443-B1 | PROCESS FOR PRODUCING IMINE COMPOUNDS FOR COMBATING INVERTEBRATE PESTS | BASF SE (DE) | 2015-02-18 | — | — | EP | disclosed |
| US-8633231-B2 | Substituted imidazolones, compositions containing such compounds and methods of use | MERCK SHARP & DOHME CORP. (US) | 2014-01-21 | — | — | US | disclosed |
| US-20130123315-A1 | SUBSTITUTED IMIDAZOLONES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | MERCK SHARP & DOHME LLC | 2013-05-16 | — | — | US | disclosed |
| EP-2552209-A1 | NOVEL SPIRO IMIDAZOLONE DERIVATIVES AS GLUCAGON RECEPTOR ANTAGONISTS, COMPOSITIONS, AND METHODS FOR THEIR USE | Merck Sharp & Dohme Corp. (US) | 2013-02-06 | — | — | EP | disclosed |
| US-20130012493-A1 | NOVEL SPIRO IMIDAZOLONE DERIVATIVES AS GLUCAGON RECEPTOR ANTAGONISTS, COMPOSITIONS, AND METHODS FOR THEIR USE | MERCK SHARP & DOHME CORP. | 2013-01-10 | — | — | US | disclosed |
| WO-2012009226-A1 | SUBSTITUTED IMIDAZOLONES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | MERCK SHARP & DOHME CORP. (US) | 2012-01-19 | — | — | WO | disclosed |
| WO-2011119541-A1 | NOVEL SPIRO IMIDAZOLONE DERIVATIVES AS GLUCAGON RECEPTOR ANTAGONISTS, COMPOSITIONS, AND METHODS FOR THEIR USE | SCHERING CORPORATION (US) | 2011-09-29 | — | — | WO | disclosed |
| US-6846957-B2 | Synthesis of 3-aminomethyl-1-propanol, a fluoxetine precursor | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2005-01-25 | — | — | US | disclosed |
| US-20040102651-A1 | Synthesis of 3-aminomethyl-1-propanol, a fluoxetine precursor | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2004-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130012493-A1 | NOVEL SPIRO IMIDAZOLONE DERIVATIVES AS GLUCAGON RECEPTOR ANTAGONISTS, COMPOSITIONS, AND METHODS FOR THEIR USE | GLP1R, GCGR, GIPR | LMNA 1719/4885SIGMAR1 2217/4885MEN1 908/4885 |
| US-20230203027-A1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | RIPK1, RIPK2, RIPK3 | LMNA 3512/4885SIGMAR1 2075/4885MEN1 4437/4885 |
| US-20240109882-A1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | RIPK1, RIPK2, RIPK3 | LMNA 3512/4885SIGMAR1 2075/4885MEN1 4437/4885 |
| US-11897876-B2 | Isoxazolidines as RIPK1 inhibitors and use thereof | RIPK1, RIPK2, RIPK3 | LMNA 3512/4885SIGMAR1 2075/4885MEN1 4437/4885 |
| US-20130123315-A1 | SUBSTITUTED IMIDAZOLONES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | UGT2B7, CYP3A43, UGT1A7 | LMNA 525/4885SIGMAR1 2057/4885MEN1 738/4885 |
| US-20040102651-A1 | Synthesis of 3-aminomethyl-1-propanol, a fluoxetine precursor | TPH1, HTR1A, TPH2 | LMNA 1046/4885SIGMAR1 351/4885MEN1 975/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.